The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | The importance of genomic testing in CLL in the era of novel therapies
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the importance of genomic testing in chronic lymphocytic leukemia (CLL) in the era of novel agents, and further highlights the value of testing for del(17p) with fluorescence in situ hybridization (FISH), as well as IgHV and TP53 mutational status. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
